Amarin Announces Agreement From FDA on Special Protocol Assessment for AMR101 Outcomes Study
August 10, 2011 04:00 ET
|
Amarin Corporation plc
MYSTIC, Conn. and DUBLIN, Ireland, Aug. 10, 2011 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today...
Amarin Reports Second Quarter 2011 Results
August 09, 2011 17:00 ET
|
Amarin Corporation plc
- Company on Track for NDA Filing This Quarter -
- Conference Call Set for 8:00 am EDT August 10 -
MYSTIC, Conn. and DUBLIN, Aug. 9, 2011 (GLOBE NEWSWIRE) -- Amarin Corporation plc...
Amarin to Present at the 2011 Canaccord Genuity Growth Conference
August 08, 2011 07:05 ET
|
Amarin Corporation plc
MYSTIC, Conn. and DUBLIN, Aug. 8, 2011 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today announced that...
Amarin Announces Q2, 2011 Results Conference Call
August 08, 2011 07:00 ET
|
Amarin Corporation plc
MYSTIC, Conn. and DUBLIN, Aug. 8, 2011 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a clinical-stage biopharmaceutical company focused on cardiovascular disease, has scheduled a...
Phase 3 ANCHOR and MARINE Trial Data to be Presented in November at the American Heart Association's Scientific Sessions
August 04, 2011 08:00 ET
|
Amarin Corporation plc
MYSTIC, Conn. and DUBLIN, Ireland, Aug. 4, 2011 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today...
Amarin Successfully Completes All Remaining Clinical Studies for AMR101 NDA
August 01, 2011 08:00 ET
|
Amarin Corporation plc
MYSTIC, Conn. and DUBLIN, Ireland, Aug. 1, 2011 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, announced...
Amarin Completes All Non-Clinical Work for AMR101 NDA Submission
July 07, 2011 03:00 ET
|
Amarin Corporation plc
MYSTIC, Conn. and DUBLIN, July 7, 2011 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, announced today the...
Amarin to Present at the Jefferies 2011 Global Healthcare Conference
June 01, 2011 07:00 ET
|
Amarin Corporation plc
MYSTIC, Conn. and DUBLIN, Ireland, June 1, 2011 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today...
Amarin Announces Global Supply Network for AMR101
May 31, 2011 02:00 ET
|
Amarin Corporation plc
MYSTIC, Conn. and DUBLIN, May 31, 2011 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, announced today the...
Additional Detail of Successful MARINE Phase III Trial to be Presented at the National Lipid Association 2011 Annual Scientific Sessions
May 19, 2011 08:54 ET
|
Amarin Corporation plc
NEW YORK, May 19, 2011 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today summarized additional MARINE...